**7. Conclusion**

Nowadays, the advancements in cell marketing with the progress in cell isolation, description, and quality control will positively encourage scientists to apply MSCs for treating several diseases and disorders, even with all remaining challenges.

Preclinical studies revealed the importance of MSC therapy in the SCI and paraplegia field. Unluckily, the effect of MSC therapy is not typically seen in the human studies, and the results need a long time from being similar to preclinical studies. Consequently, among other concerns, the protocol standardization in source of cells, culture conditions, time of cell delivery after paraplegia, number and administration rout of cells, plasticity, and potential of MSCs after isolation and expansion in vitro is of urgency. Confidently, preliminary studies with emphasis on these key points will be helpful in terms of their winning implementation of human studies.
